11 research outputs found
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis: a randomised, controlled, open-label, platform trial and updated meta-analysis
No full textBackground: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was done, which included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936) and is ongoing. Findings: Between Feb 2 and Dec 29, 2021, from 10 852 enrolled, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% were receiving tocilizumab (with planned use within the next 24 h recorded for a further 9%). Overall, 514 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0·87; 95% CI 0·77–0·99; p=0·028). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of eight previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths), in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0·57; 95% CI 0·45–0·72). Including the results from RECOVERY in an updated meta-analysis of all nine completed trials (involving 11 888 randomly assigned patients and 1485 deaths) allocation to baricitinib or another JAK inhibitor was associated with a 20% proportional reduction in mortality (rate ratio 0·80; 95% CI 0·72–0·89; p<0·0001). In RECOVERY, there was no significant excess in death or infection due to non-COVID-19 causes and no significant excess of thrombosis, or other safety outcomes. Interpretation: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomised evidence to date suggests that JAK inhibitors (chiefly baricitinib) reduce mortality in patients hospitalised for COVID-19 by about one-fifth. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial: a randomised, controlled, open-label, platform trial
No full textBackground: Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group. Methods: This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting adult patients with clinical evidence of hypoxia (ie, receiving oxygen or with oxygen saturation <92% on room air) were randomly allocated (1:1) to either usual care with higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg dexamethasone once daily for 5 days or until discharge if sooner) or usual standard of care alone (which included dexamethasone 6 mg once daily for 10 days or until discharge if sooner). The primary outcome was 28-day mortality among all randomised participants. On May 11, 2022, the independent data monitoring committee recommended stopping recruitment of patients receiving no oxygen or simple oxygen only due to safety concerns. We report the results for these participants only. Recruitment of patients receiving ventilatory support is ongoing. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between May 25, 2021, and May 13, 2022, 1272 patients with COVID-19 and hypoxia receiving no oxygen (eight [1%]) or simple oxygen only (1264 [99%]) were randomly allocated to receive usual care plus higher dose corticosteroids (659 patients) versus usual care alone (613 patients, of whom 87% received low-dose corticosteroids during the follow-up period). Of those randomly assigned, 745 (59%) were in Asia, 512 (40%) in the UK, and 15 (1%) in Africa. 248 (19%) had diabetes and 769 (60%) were male. Overall, 123 (19%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of 613 patients allocated to usual care died within 28 days (rate ratio 1·59 [95% CI 1·20–2·10]; p=0·0012). There was also an excess of pneumonia reported to be due to non-COVID infection (64 cases [10%] vs 37 cases [6%]; absolute difference 3·7% [95% CI 0·7–6·6]) and an increase in hyperglycaemia requiring increased insulin dose (142 [22%] vs 87 [14%]; absolute difference 7·4% [95% CI 3·2–11·5]). Interpretation: In patients hospitalised for COVID-19 with clinical hypoxia who required either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared with usual care, which included low-dose corticosteroids. The RECOVERY trial continues to assess the effects of higher dose corticosteroids in patients hospitalised with COVID-19 who require non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation. Funding: UK Research and Innovation (Medical Research Council), National Institute of Health and Care Research, and Wellcome Trust
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial: a randomised, controlled, open-label, platform trial
No full textBackground: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19. Methods: RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19. 127 UK hospitals took part in the evaluation of casirivimab and imdevimab. Eligible participants were any patients aged at least 12 years admitted to hospital with clinically suspected or laboratory-confirmed SARS-CoV-2 infection. Participants were randomly assigned (1:1) to either usual standard of care alone or usual care plus casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion. Investigators and data assessors were masked to analyses of the outcome data during the trial. The primary outcome was 28-day all-cause mortality assessed by intention to treat, first only in patients without detectable antibodies to SARS-CoV-2 infection at randomisation (ie, those who were seronegative) and then in the overall population. Safety was assessed in all participants who received casirivimab and imdevimab. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between Sept 18, 2020, and May 22, 2021, 9785 patients enrolled in RECOVERY were eligible for casirivimab and imdevimab, of which 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. 3153 (32%) of 9785 patients were seronegative, 5272 (54%) were seropositive, and 1360 (14%) had unknown baseline antibody status. 812 (8%) patients were known to have received at least one dose of a SARS-CoV-2 vaccine. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio [RR] 0·79, 95% CI 0·69–0·91; p=0·0009). In an analysis of all randomly assigned patients (regardless of baseline antibody status), 943 (19%) of 4839 patients allocated to casirivimab and imdevimab versus 1029 (21%) of 4946 patients allocated to usual care died within 28 days (RR 0·94, 95% CI 0·86–1·02; p=0·14). The proportional effect of casirivimab and imdevimab on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity=0·002). There were no deaths attributed to the treatment, or meaningful between-group differences in the pre-specified safety outcomes of cause-specific mortality, cardiac arrhythmia, thrombosis, or major bleeding events. Serious adverse reactions reported in seven (<1%) participants were believed by the local investigator to be related to treatment with casirivimab and imdevimab. Interpretation: In patients admitted to hospital with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab reduced 28-day mortality in patients who were seronegative (and therefore had not mounted their own humoral immune response) at baseline but not in those who were seropositive at baseline. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial: a randomised, controlled, open-label, platform trial
No full textBackground: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial: a randomised controlled, open-label, platform trial
No full textBackground: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial: a randomised, controlled, open-label, platform trial
No full textBackground: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods: In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24). Interpretation: In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial: a randomised, controlled, open-label, platform trial
No full textBackground: Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19. Methods: In this randomised, controlled, open-label, platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. The trial took place at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care plus 150 mg aspirin once per day until discharge or usual standard of care alone using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28 day mortality. All analyses were done by intention to treat. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between Nov 1, 2020, and March 21, 2021, 14 892 (66%) of 22 560 patients enrolled into the RECOVERY trial were eligible to be randomly allocated to aspirin. 7351 patients were randomly allocated (1:1) to receive aspirin and 7541 patients to receive usual care alone. Overall, 1222 (17%) of 7351 patients allocated to aspirin and 1299 (17%) of 7541 patients allocated to usual care died within 28 days (rate ratio 0·96, 95% CI 0·89–1·04; p=0·35). Consistent results were seen in all prespecified subgroups of patients. Patients allocated to aspirin had a slightly shorter duration of hospitalisation (median 8 days, IQR 5 to >28, vs 9 days, IQR 5 to >28) and a higher proportion were discharged from hospital alive within 28 days (75% vs 74%; rate ratio 1·06, 95% CI 1·02–1·10; p=0·0062). Among patients not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (21% vs 22%; risk ratio 0·96, 95% CI 0·90–1·03; p=0·23). Aspirin use was associated with a reduction in thrombotic events (4·6% vs 5·3%; absolute reduction 0·6%, SE 0·4%) and an increase in major bleeding events (1·6% vs 1·0%; absolute increase 0·6%, SE 0·2%). Interpretation: In patients hospitalised with COVID-19, aspirin was not associated with reductions in 28 day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days. Funding: UK Research and Innovation (Medical Research Council), National Institute of Health Research, and the Wellcome Trust through the COVID-19 Therapeutics Accelerator
JOURNAL OF HUMAN KINETICS AND HEALTH EDUCATION PEDAGOGY
No full text© Department of Human Kinetics and Health Education Faculty of Education,
Ekiti State University, Ado-Ekiti Nigeria.
Website: www.humankineticsedu.com
All right reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the Editor-in-Chief.
A publication of the:
Department of Human Kinetics & Health Education Faculty of Education,
Ekiti State University, Ado-Ekiti
EDITORIAL
Publishing of well researched papers in reputable journals has become an indispensable culture that must necessarily be adhered to by all academics in the university system. Now that the publishing market has been proliferated by all manners of seemingly "International Journals" the Department of Human Kinetics and Health Education, EKSU has decided to float a journal that will attain all the attributes of Real International Standards.
The birth of this journal, (Journal of Human Kinetics and Health Education Pedagogy), did not come out of the blues, but came as a result of deliberate efforts of some members of the Department, who used their many years of vast experiences in editing, reviewing and publishing quality papers in many renowned, local and international journals.
The maiden edition ensures the publication of articles from different segments of human kinetics, health education and related issues. The journal also enjoys wide- spread patronage from different authors to ascertain its global outlook.
Members of the Editorial Board wish to assure the reading public and intending authors that this journal shall be published on regular basis in conformity with the dynamic trend in academic world. Our appreciation goes to the Heads of Department, past and present, the Professors and other members of the Department for their contributions to the successful launch of this journal.
Professor Isaac Olusola AKINDUTIRE,
Editor- In- Chief
EDITORIAL BOARD
Editor –in-Chief - Professor I. O. Akindutire
Managing Editor - Professor J. A. Adegboyega
Acting Head of Department - Dr. O.M. Bolarinwa
Consulting Editors
Prof. A. L. Toriola - Tehwane University of Technology,South Africa Prof. E. B. Okunrotifa - Obafemi Awolowo University, Ile-Ife
Prof. J. F. Babalola - University of Ibadan, Ibadan
Prof. Pat Oyeniyi - Ekiti State University, Ado-Ekiti
Prof. J. A. Adegun - Ekiti State University, Ado-Ekiti
Prof. O. O. Obiyemi - University of Ilorin, Ilorin, Kwara State
Prof. C. A. Ajibola - University of Calabar
Prof. L. O. Eboh - Delta State University, Abraka
Prof. A. O. Akeredolu - Lagos State University, Ojoo, Lagos
Prof. B. O. Ogundele - University of Ibadan, Ibadan
Publication Committee
Prof. J. A. Adegboyega - Chairman
Prof. O. B. Ajayi-Vincent - Member
Dr. (Mrs.) E. O. Adeloye - Member
Mrs. O. O. Aina - Member
Dr (Mrs.) A. O. Awosusi - Secretary
GUIDELINES FOR PAPER SUBMISSION
Only manuscripts that adhere to the guidelines below will be accepted for publication in the Journal of Human Kinetics and Health Education:
The manuscript should be typed in double line space on A4 size paper with Microsoft words, Times New Roman, 12 point font size, preferred manuscript length is 12 typewritten pages.
The title of article, author\u27s name and affiliation and the full address, showing e-mail address and mobile phone number to which correspondence should be sent must be submitted on a separate sheet.
The abstract must not be more than 200 italicized words with focus on the purpose, methods, findings and recommendations; and a maximum of five key words.
Tables and figures are to be fixed appropriately in the manuscript. Tables should be in 2 decimal places and levels of significance clearly stated, where applicable.
Materials forwarded to the Journal for consideration should be original and not have been submitted to another publication or published elsewhere.
The current APA style of referencing should be adapted. Visit apastyle.org
Paper acceptance notification will be made known to contributors within 2 weeks after paper submission.
The Journal does not charge submission fee like other
It is expected that the publication will be out by July,
Papers for publication should be submitted electronically as attachment, preferably in word document file, to the editor via the e-mail below:
[email protected]; Copy: [email protected], [email protected]
FOR FURTHER ENQUIRIES
All Correspondence address to:
Editor-In-Chief Editor:
Prof. I. O. Akindutire Prof. J. A. Adegboyega,
Department of Human Kinetics Department of Human Kinetics
& Health Education, & Health Education,
Faculty of Education, Faculty of Education,
Ekiti State University, Ado-Ekiti Ekiti State University, Ado-Ekiti
+2348033738145 +2348037400188
Assistant Editor Ag. Head of Department
Dr. (Mrs.) A. O. Awosusi Dr. O.M. Bolarinwa
Department of Human Kinetics Department of Human Kinetics
& Health Education, & Health Education,
Faculty of Education, Faculty of Education,
Ekiti State University, Ado-Ekiti Ekiti State University, Ado-Ekiti
+2348030707463 +2348065713422
 
JOURNAL OF HUMAN KINETICS AND HEALTH EDUCATION PEDAGOGY: Exploring the Environment for Sustainable Development: The Plight of Nigerian Children
No full textDepartment of Human Kinetics and Health Education Faculty of Education,
Ekiti State University, Ado-Ekiti Nigeria.
Website: www.humankineticsedu.com
All right reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the Editor-in-Chief.
A publication of the:
Department of Human Kinetics & Health Education Faculty of Education,
Ekiti State University, Ado-Ekiti
EDITORIAL
Publishing of well researched papers in reputable journals has become an indispensable culture that must necessarily be adhered to by all academics in the university system. Now that the publishing market has been proliferated by all manners of seemingly "International Journals" the Department of Human Kinetics and Health Education, EKSU has decided to float a journal that will attain all the attributes of Real International Standards.
The birth of this journal, (Journal of Human Kinetics and Health Education Pedagogy), did not come out of the blues, but came as a result of deliberate efforts of some members of the Department, who used their many years of vast experiences in editing, reviewing and publishing quality papers in many renowned, local and international journals.
The maiden edition ensures the publication of articles from different segments of human kinetics, health education and related issues. The journal also enjoys wide- spread patronage from different authors to ascertain its global outlook.
Members of the Editorial Board wish to assure the reading public and intending authors that this journal shall be published on regular basis in conformity with the dynamic trend in academic world. Our appreciation goes to the Heads of Department, past and present, the Professors and other members of the Department for their contributions to the successful launch of this journal.
Professor Isaac Olusola AKINDUTIRE, Editor- In- Chief
EDITORIAL BOARD
Editor –in-Chief - Professor I. O. Akindutire
Managing Editor - Professor J. A. Adegboyega Acting Head of Department - Dr. (Mrs.) P. E. Konwea
Consulting Editors
Prof. A. L. Toriola - Tehwane University of Technology, Pretoria, South Africa
Prof. E. B. Okunrotifa - Obafemi Awolowo University, Ile-Ife
Prof. J. F. Babalola - University of Ibadan, Ibadan
Prof. J. B. Omonu - Ibrahim Babangida University, Lapai, Niger State, Nigeria
Prof. J. A. Adegun - Ekiti State University, Ado-Ekiti
Prof. O. O. Obiyemi - University of Ilorin, Ilorin, Kwara State
Prof. C. A. Ajibola - University of Calabar
Prof. L. O. Eboh - Delta State University, Abraka
Prof. A. O. Akeredolu - Lagos State University, Ojoo, Lagos
Prof. B. O. Ogundele - University of Ibadan, Ibadan
Publication Committee
Prof. J. A. Adegboyega - Chairman
Prof. O. B. Ajayi -Vincent - Member
Dr. (Mrs.) E. O. Adeloye - Member
Mrs. O. O. Aina - Member
Dr (Mrs.) A. O. Awosusi - Secretary
GUIDELINES FOR PAPER SUBMISSION
Only manuscripts that adhere to the guidelines below will be accepted for publication in the Journal of Human Kinetics and Health Education:
The manuscript should be typed in double line space on A4 size paper with Microsoft words, Times New Roman, 12 point font size, preferred manuscript length is 12 typewritten pages.
The title of article, author\u27s name and affiliation and the full address, showing e-mail address and mobile phone number to which correspondence should be sent must be submitted on a separate
The abstract must not be more than 200 italicized words with focus on the purpose, methods, findings and recommendations; and a maximum of five key words.
Tables and figures are to be fixed appropriately in the manuscript. Tables should be in 2 decimal places and levels of significance clearly stated, where applicable.
Materials forwarded to the Journal for consideration should be original and not have been submitted to another publication or published elsewhere.
The current APA style of referencing should be Visit www.apastyle.org
Paper acceptance notification will be made known to contributors within 2 weeks after paper
The Journal does not charge submission fee like other
It is expected that the publication will be out by July,
Papers for publication should be submitted electronically as attachment, preferably in word document file, to the editor via the e-mail below:
[email protected]; Copy: [email protected], [email protected]
FOR FURTHER ENQUIRIES
All Correspondence address to:
Editor-In-Chief Editor:
Prof. I. O. Akindutire Prof. J. A. Adegboyega,
Department of Human Kinetics Department of Human Kinetics
& Health Education, & Health Education,
Faculty of Education, Faculty of Education,
Ekiti State University, Ado-Ekiti Ekiti State University, Ado-Ekiti
+2348033738145 +2348037400188
Assistant Editor Ag. Head of Department
Dr. (Mrs.) A. O. Awosusi Dr. (Mrs.) P.E. Konwea
Department of Human Kinetics Department of Human Kinetics
& Health Education, & Health Education,
Faculty of Education, Faculty of Education,
Ekiti State University, Ado-Ekiti Ekiti State University, Ado-Ekiti
+2348030707463 +2348033952887
 
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
No full textBackground
Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group.
Methods
This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting adult patients with clinical evidence of hypoxia (ie, receiving oxygen or with oxygen saturation <92% on room air) were randomly allocated (1:1) to either usual care with higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg dexamethasone once daily for 5 days or until discharge if sooner) or usual standard of care alone (which included dexamethasone 6 mg once daily for 10 days or until discharge if sooner). The primary outcome was 28-day mortality among all randomised participants. On May 11, 2022, the independent data monitoring committee recommended stopping recruitment of patients receiving no oxygen or simple oxygen only due to safety concerns. We report the results for these participants only. Recruitment of patients receiving ventilatory support is ongoing. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
Findings
Between May 25, 2021, and May 13, 2022, 1272 patients with COVID-19 and hypoxia receiving no oxygen (eight [1%]) or simple oxygen only (1264 [99%]) were randomly allocated to receive usual care plus higher dose corticosteroids (659 patients) versus usual care alone (613 patients, of whom 87% received low-dose corticosteroids during the follow-up period). Of those randomly assigned, 745 (59%) were in Asia, 512 (40%) in the UK, and 15 (1%) in Africa. 248 (19%) had diabetes and 769 (60%) were male. Overall, 123 (19%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of 613 patients allocated to usual care died within 28 days (rate ratio 1·59 [95% CI 1·20–2·10]; p=0·0012). There was also an excess of pneumonia reported to be due to non-COVID infection (64 cases [10%] vs 37 cases [6%]; absolute difference 3·7% [95% CI 0·7–6·6]) and an increase in hyperglycaemia requiring increased insulin dose (142 [22%] vs 87 [14%]; absolute difference 7·4% [95% CI 3·2–11·5]).
Interpretation
In patients hospitalised for COVID-19 with clinical hypoxia who required either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared with usual care, which included low-dose corticosteroids. The RECOVERY trial continues to assess the effects of higher dose corticosteroids in patients hospitalised with COVID-19 who require non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation
